Dr. Stephanie Tsai
Claim this profileLoyola University Medical Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
14 reported clinical trials
32 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
BCR-ABL1 positive
PML-RARA negative
CD22 positive
2Acute Myeloid Leukemia
PML-RARA negative
FLT3 positive
FLT3 negative
Affiliated Hospitals
Clinical Trials Stephanie Tsai is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
More about Stephanie Tsai
Clinical Trial Related6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Stephanie Tsai has experience with
- Azacitidine
- Cytarabine
- Venetoclax
- Daunorubicin Hydrochloride
- Blinatumomab
- Inotuzumab Ozogamicin
Breakdown of trials Stephanie Tsai has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephanie Tsai specialize in?
Stephanie Tsai focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved BCR-ABL1 positive patients, or patients who are PML-RARA negative.
Is Stephanie Tsai currently recruiting for clinical trials?
Yes, Stephanie Tsai is currently recruiting for 9 clinical trials in Maywood Illinois. If you're interested in participating, you should apply.
Are there any treatments that Stephanie Tsai has studied deeply?
Yes, Stephanie Tsai has studied treatments such as Azacitidine, Cytarabine, Venetoclax.
What is the best way to schedule an appointment with Stephanie Tsai?
Apply for one of the trials that Stephanie Tsai is conducting.
What is the office address of Stephanie Tsai?
The office of Stephanie Tsai is located at: Loyola University Medical Center, Maywood, Illinois 60153 United States. This is the address for their practice at the Loyola University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.